Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach

Paolo Innocenti,† Hannah L. Woodward,† Savade Solanki,† Sébastien Naud,† Isaac M. Westwood,† Nora Cronin,‡ Angela Hayes,† Jennie Roberts,† Alan T. Henley,† Ross Baker,† Amir Faisal,∥ Grace Wing-Yan Mak,† Gary Box,† Melanie Valenti,† Alexis De Haven Brandon,† Lisa O’Fee,† Harry Saville,† Jessica Schmitt,† Berry Matijssen,† Rosemary Burke,† Rob L. M. van Montfort,†‡ Florence I. Raynaud,† Suzanne A. Eccles,† Spiros Linardopoulos,†§ Julian Blagg,† and Swen Hoelder*†

†Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, United Kingdom
‡Division of Structural Biology and §Breast Cancer Now, Division of Breast Cancer Research, The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, United Kingdom

Supporting Information

ABSTRACT: Monopolar spindle 1 (MPS1) plays a central role in the transition of cells from metaphase to anaphase and is one of the main components of the spindle assembly checkpoint. Chromosomally unstable cancer cells rely heavily on MPS1 to cope with the stress arising from abnormal numbers of chromosomes and centrosomes and are thus more sensitive to MPS1 inhibition than normal cells. We report the discovery and optimization of a series of new pyrido[3,4-d]pyrimidine based inhibitors via a structure-based hybridization approach from our previously reported inhibitor CCT251455 and a modestly potent screening hit. Compounds in this novel series display excellent potency and selectivity for MPS1, which translates into biomarker modulation in an in vivo human tumor xenograft model.

INTRODUCTION

Interfering with mitotic processes has been a successful therapeutic approach to fight cancer. One example of a mitotic target is monopolar spindle 1 (MPS1, also known as TTK), a dual-specificity kinase that occupies a central role in the transition from metaphase to anaphase and is one of the main components of the spindle assembly checkpoint (SAC). This kinase prevents cells from progressing through mitosis until the kinetochores are properly attached to the microtubules and are under the appropriate tension. While this mechanism is important to ensure error-free segregation of chromosomes in normal tissues, aneuploid and chromosomally unstable cancer cells are more dependent on MPS1 to cope with the stress arising from abnormal numbers of chromosomes and centrosomes. Due to these findings, it is not surprising that MPS1 is upregulated in a number of tumor types and that higher levels correlate with higher histological grade, aggressiveness, and poorer patient survival in breast cancer, glioblastoma, and pancreatic ductal adenocarcinoma. Furthermore, phosphatase and tensin homologue (PTEN)-deficient breast cancer cell lines have been reported to be more sensitive to MPS1 depletion or kinase inhibition.

Using advanced inhibitors, including our own 1 (CCT251455, vide infra), effective dosing schedules have been investigated in vivo. Importantly, it has recently been shown that MPS1 inhibitors have a relatively narrow therapeutic window and that they are particularly effective when used in combination...
with, for example, tubulin-targeting agents such as paclitaxel or CDK4/6 inhibitors.9

Several MPS1 inhibitors have been disclosed,10 these include AstraZeneca’s AZ3146 (2),10b the Myrexis compound MPI-0479605 (3),8c and the Nerviano compound NMS-P715 (4).11 Also described in the literature are MPS-IN-3 (5),5a CFI-401870 (6),12 and the Shionogi compounds (7, 8) (Figure 1).8a,13

We recently disclosed a series of 1H-pyrrolo[3,2-c]pyridines exemplified by the potent and selective chemical probe 1.7 However, while this compound showed excellent potency in biochemical and cellular assays, other properties hampered further development. In particular, 1 has a relatively high molecular weight (504) and AlogP (5.7) and also featured a tert-butoxycarbonyl (Boc) moiety that appeared critical for potent inhibition but unsurprisingly proved to be unstable under strongly acidic conditions.14 In addition, 1 was a potent cytochrome P450 (CYP) inhibitor (IC50 < 1 μM observed for CYP 1A2, 3A4, 2C9, 2C19, 2D6) which represented a significant issue not least because MPS1 inhibitors are reported to be particularly effective in combination with other chemotherapeutic agents, e.g., paclitaxel. To mitigate the risk that these undesirable features were inherent to the 1H-pyrrolo[3,2-c]pyridine series, we set out to discover a second structurally unrelated chemotype featuring a clean CYP profile, no acid labile groups, and significantly lower molecular weight and lipophilicity. We thus set out to discover an additional lead series that (a) showed potent inhibition of MPS1 in cellular assays (IC50 < 100 nM), (b) showed good ligand efficiency (L.E. ~ 0.35),15 (c) displayed excellent selectivity, in particular against other cell cycle kinases such as cyclin-dependent kinase 2 (CDK2), Aurora A and B, and more generally against the wider kinome (Ki ratio >100), (d) robustly modulated MPS1 kinase activity in a human tumor xenograft PK/PD model, and (e) showed significant scope for further modification.

Herein we describe the rapid discovery of such a series by structure-based hybridization of the 1H-pyrrolo[3,2-c]pyridine series and a modestly potent hit from a focused kinase library screen. This completely new MPS1 series featured an unexploited kinase chemotype (the pyrido[3,4-d]pyrimidines) and advanced examples displayed subnanomolar Ki and excellent overall selectivity. The favorable in vitro properties translated into biomarker modulation in an in vivo human tumor xenograft model.

**CHEMISTRY**

The synthesis of isoquinolines 14, 15a and 15b was carried out from the commercially available 5-bromo-3-chloroisoquinoline 9 through sequential Suzuki couplings and Buchwald reactions using suitable boronic acids or esters and the required anilines (Scheme 1).

Compounds 24a–d and 28a–e in the pyrido[3,4-d]pyrimidine series were prepared according to a previously described strategy which makes use of the novel 8-chloro-2-(methylthio)pyrido[3,4-d]pyrimidine building block 16.16 Thus, reaction with 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, Na2CO3, Pd(dppf)Cl2·CH2Cl2, DME/water, μW, 105 °C; (b) 4-methoxyaniline 12 or 2,4-dimethoxyaniline 13, ‘BuXPhos, Pd2dba3, Cs2CO3, ‘BuOH/water, μW, 80–100 °C. Reaction yields are in parentheses.

![Figure 1. Published MPS1 inhibitors.](image)

**Scheme 1. Synthesis of Isoquinoline Derivatives**

![Scheme 1](image)
using m-CPBA and subsequently coupled with the required anilines or formamides to afford compounds 24a–d (Scheme 2). In the majority of cases though, the order of events was reversed. Oxidation of 8-chloro-2-(methylthio)pyrido[3,4-d]pyrimidine 16 yielded the corresponding sulfone 25,16 which was coupled with a series of formamides furnishing chloro-intermediates 27a–e (Scheme 2). Final compounds 28a–e were obtained by means of palladium-catalyzed Suzuki couplings with commercially available boronic acids or esters. Pyrido[3,4-d]pyrimidines 33a and 33b were prepared by direct substitution of amines on the 8-chloro-2-(methylthio)pyrido[3,4-d]pyrimidine building block 16 (Scheme 3). The resulting thiomethyl derivatives 29 and 30 were oxidized to the corresponding sulfones 31 and 32 and subsequently coupled with the required formamides to afford final compounds 33a and 33b.

Pyrido[3,4-d]pyrimidines 34a–h were prepared from intermediate 27a16 by displacement using the appropriate nucleophiles (Scheme 4). In one instance the synthetic strategy involved the use of known pyridine 3516 as a starting material: O-alkylation in the presence of base and bromomethyl cyclopropane gave intermediate 36. Oxidation using m-CPBA and subsequent coupling with formamide 26a16 afforded pyrido[3,4-d]pyrimidine 38 (Scheme 4). In all cases, formamides and anilines were commercially available (12, 13, 21) or could be synthesized by means of standard transformations (22, 23, 17 and 26a–e, see Experimental).

Reagents and conditions: (a) 1-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, Na2CO3, Pd(dppf)Cl2·CH2Cl2, THF/water, 65 °C (17); (b) cyclopropyl boronic acid, K3PO4, Pd(OAc)2, PCy3, toluene/water, 95 °C (18); (c) m-CPBA, CH2Cl2, rt; (d) N-(4-methoxyphenyl)formamide 21 or N-(2,4-dimethoxyphenyl)formamide 22, DMSO, Cs2CO3, 100 °C (24a,b); (e) 2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)aniline 23, TFA, 1,2,3-trifluoroethanol, μW, 130 °C (24c,d); (f) ArNHCHO (26a–e), NaH, THF, rt; (g) 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole or phenyl boronic acid, Cs2CO3, Pd(PPh3)4, 1,4-dioxane/water, 100 °C. Reaction yields are in parentheses.
RESULTS AND DISCUSSION

At the start of this work, relatively few inhibitors of MPS1 had been disclosed. In addition to our 1H-pyrrolo[3,2-c]pyridine series,7 we had identified and crystallized 1H-pyrazolo[4,3-c]pyridine 39, a modestly potent hit, during an initial screening campaign. This compound showed low molecular weight (MW = 261) and acceptable ligand efficiency (L.E. = 0.43). The crystal structure of MPS1 in complex with 39 revealed that it binds in a complementary way to 4, whereby the pyrazole moiety binds to the hinge region of the protein. The furan moiety occupies the same region as the carbamate in the 1H-pyrrolo[3,2-c]pyridine series. The phenyl ring and aniline moiety also occupy similar parts of the binding pocket (Figure 2).18 Based on these results, we anticipated that 39 would represent a viable starting point for a second series but that extensive optimization of potency and selectivity would be required. In order to rapidly discover a new series, while utilizing previously gained SAR data, we merged the 1H-pyrrolo[3,2-c]pyridine scaffold with the screening hit 39 (Figure 3). Docking suggested that both the isoquinoline and pyrido[3,4-d]pyrimidine scaffolds could serve as hinge-binder elements for such a hybrid series (Figure 3). The isoquinoline scaffold had the advantage that proof-of-concept molecules could be rapidly prepared using precedented chemistry and commercially available building blocks. The pyrido[3,4-d]pyrimidine scaffold, on the other hand, was attractive from the point of view of novelty, the significantly lower lipophilicity, and the fact that it incorporated an additional pyridine nitrogen from screening hit 39. This scaffold, however, required significant investigation into its synthesis.16 Our plan was thus to prepare a select number of

Scheme 3. Functionalization of Pyrido[3,4-d]pyrimidine Core

Scheme 4. Synthesis of Derivatives Containing 8-Position N, O, and S Substituents

“Reagents and conditions: (a) Amine, NMP, 80–135 °C; (b) m-CPBA, CH₂Cl₂, rt; (c) 2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)aniline 23, TFA, 1,2,3-trifluoroethanol, μW, 130 °C. Reaction yields are in parentheses.

“Reagents and conditions: (a) Amine, NMP, 80–135 °C (34a–e, g, h); (b) cyclohexyl thiol, K₂CO₃, DMF, rt (34f); (c) Ag₂CO₃, bromomethyl cyclopropane, CHCl₃, rt to 60 °C; (d) m-CPBA, CH₂Cl₂, rt; (e) N-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)formamide 26a, NaH, THF, rt. Reaction yields are in parentheses.
The data for the initial set of compounds are summarized in Table 1. The MPS1 inhibition for 14 was modest (IC₅₀ = 3.66 μM, Table 1), but replacing the furan with a pyrazole (15a) not only lowered lipophilicity but also gave a 5-fold increase in potency (Table 1). Moreover, incorporating an additional methoxy group led to a significant gain in potency, and the IC₅₀ of 15b reached our goal for an initial proof-of-concept compound. As seen with the 1H-pyrralo[3,2-c]pyrimidines, the latter greatly improved selectivity toward CDK2. The significant gain in potency can be ascribed to the interaction of the aniline’s 2-methoxy substituent with a small hydrophobic pocket formed by Lys529, Ile531, Glu541, and Cys604. This pocket is not present in most other kinases including CDK2, explaining the beneficial effect on kinase selectivity.

Having achieved satisfactory potency and ligand efficiency (L.E. for 15b = 0.36) by merging the 1H-pyrralo[3,2-c]pyrimidine series and screening hit 39, we investigated the less lipophilic pyrido[3,4-d]pyrimidine scaffold. Gratifyingly, 8-substituted 2-anilino-pyrido[3,4-d]pyrimidines proved to be more potent than their isoquinoline counterparts, reaching the double digit nanomolar range despite significantly lower calculated logP (Table 1). Isoquinoline 15b along with pyrido[3,4-d]-pyrimidines 24a and 24b were next tested in an MSD-based cellular assay. Both 15b and 24b showed only modest inhibition of the autophosphorylation of ectopically expressed MPS1 in HCT116 cells, most likely due to suboptimal biochemical potency. In the 1H-pyrralo[3,2-c]pyrimidine series, introduction of a pyrazole substituent at the 4-position of the aniline caused a significant increase in biochemical and cellular potency. Gratifyingly, this structural modification also resulted in a further improvement in biochemical potency for the pyrido[3,4-d]pyrimidine series, with compound 24c achieving a MPS1 IC₅₀ = 0.008 μM and a cellular P-MPS1 IC₅₀ = 0.604 μM (Table 1).

We solved the crystal structure of MPS1 in complex with isoquinoline 15b and pyrido[3,4-d]pyrimidine 24b (Figure 4). The two structures overlaid very well with the crystal structure of 1 (Figure 4A and B), binding to the hinge region through the same motif as seen with the 1H-pyrralo[3,2-c]pyrimidines. This reinforced our initial hypothesis that merging the 1H-pyrralo[3,2-c]pyrimidine series and 39 would give a suitable starting point for an additional series of inhibitors. The aniline portion of all compounds overlapped as well as the 5-position and 8-position substituents of the isoquinolines and pyrido[3,4-d]pyrimidines.
respectively, occupying the same region as the carbamate group of 1. Of note is the difference in conformation for 15b and 24b (Figure 4C and D). The introduction of two extra nitrogen atoms into the aromatic ring, and thus removal of two hydrogen atoms, results in a much more planar structure for the pyrido[3,4-d]pyrimidine 24b. We measured the dihedral angles for both of these compounds: isoquinoline 15b exhibits a dihedral angle of 98° and pyrido[3,4-d]pyrimidine 24b exhibits a dihedral angle of −20° (Figure 4D). The more coplanar conformation of pyrido[3,4-d]pyrimidines mirrors the coplanar conformation of the carbamate function of 1 and is likely to be at least partially responsible for the improved activity seen with the much less lipophilic pyrido[3,4-d]pyrimidines. Based on these crystal structures, we had confidence that with further optimization we would achieve potent and selective pyrido[3,4-d]pyrimidine based inhibitors of MPS1.

Through our hybridization strategy and exploration of the pyrido[3,4-d]pyrimidine scaffold, we had achieved a potent inhibitor (24c, MPS1 IC50 = 0.008 μM) and for the first time reached significant levels of cellular inhibition with IC50 values below 1 μM. Compound 24c represented a promising starting point for further optimization of this compound into a novel series of MPS1 inhibitors.

Since our initial goal was to show target modulation in a human tumor xenograft model in mice, we investigated the stability of 24c in mouse liver microsomes. Unfortunately, 24c showed high turnover (MLM = 73% following 30 min incubation) and was not suitable for in vivo experiments. Metabolite ID studies suggested loss of a methyl group, and we suspected that the methoxy aniline substituent was the most likely site of demethylation. This methoxy group was important for both potency and selectivity. After consideration of the X-ray crystal structures we had in hand, suggesting that larger substituents at this position would be tolerated, we prepared and tested a series of compounds in which this putative metabolic soft spot was replaced with similar moieties (Table 2). The majority of these compounds showed higher IC50 values than 24c with the exception of the ethoxy derivative 28c, which achieved comparable potency, while exhibiting significantly improved CDK2 selectivity (>28 fold improvement over 24c) and MLM stability (MLM = 45%). This increase in selectivity is likely due to the fact that the aniline 2-position substituent occupies a small lipophilic pocket present in MPS1, mentioned previously, consisting of Lys529, Ile531, Gln541 and the gatekeeper+2 residue Cys604. This pocket is not available in CDK2 due to the presence of the bulkier gatekeeper residue Phe82. The larger 2-
position ethoxy substituent (28c) clashes with the CDK2 gatekeeper+2 residue, resulting in a better selectivity window than is seen for the methoxy derivative 24c.

Unfortunately, 28c was 5-fold less active in the cellular assay, which given the similar biochemical potency and physicochemical properties was difficult to rationalize. While we regarded the ethoxy as a valuable alternative for the methoxy group, with significantly improved selectivity and reduced risk of reactive intermediate formation through metabolic dealkylation, we decided to maintain the methoxy in place due to the improved cellular activity. Instead, we looked to improve the metabolic stability through modulation of the activation loop

In order to address these aspects we used the structural information gathered on pyrido[3,4-d]pyrimidine 24c. The crystal structure of this inhibitor showed that the 8-position pyrazole group binds to a hydrophobic pocket formed by Ile531, Val539, Met671, and Pro673 (Figure 5A). This is the same pocket that is occupied by the carbamate group of 1 and is sufficiently large to accommodate a variety of hydrophobic groups (Figure 5B). It is also of note that the crystal structure of MPS1 in complex with 24c shows ordering of the activation loop of MPS1, as is seen with 1.7 We thus prepared and tested a small set of compounds with different pyrazole replacements including a saturated pyrrolidine ring.

The data for these compounds are summarized in Table 3. The phenyl-substituted derivative (28a) showed comparable potency in the biochemical and cellular assay and, despite higher lipophilicity, improved microsomal stability. The cyclopropyl derivative 24d lost considerable activity, possibly due to the fact that this group is too small to engage in significant hydrophobic interactions. Interestingly, replacement of the pyrazole with a saturated pyrrolidine (33a) led to an equipotent compound in the biochemical assay. All compounds showed selectivity against CDK2 (CDK2/MPS1 ratio >80).

Of the compounds presented in Table 3, we considered the pyrrolidine derivative (33a) as the most promising for further optimization. A saturated moiety offered more possibilities to optimize the three-dimensional hydrophobic interactions in this subpocket compared with an aromatic ring where substituents can only be placed in the plane of the ring. Furthermore, increasing the number of sp3 centers has been suggested as a general approach to improve solubility and drug-like properties.19 We thus prepared a series of compounds with a saturated substituent in this position.

Importantly, since the IC50 values of many compounds were now approaching the enzyme concentration and thus the limit of the dynamic range of the biochemical assay, we complemented the MPS1 kinase assay at 10 μM ATP with testing at 1 mM ATP. It has been demonstrated that increasing the ATP concentration shifts the IC50 values of ATP competitive inhibitors to higher values, therefore increasing the dynamic range of the assay.20 Due to the differing ATP concentrations in the high ATP Caliper assay and the CDK2 assay (1 mM MPS1 vs 10 μM CDK2), the assays were no longer directly comparable. For this reason, we used the Cheng–Prusoff equation to calculate the Kᵈ values21 and, in turn, used these values to determine the selectivity window.

Compound 33b, incorporating a diethylamine substituent, was significantly (6-fold) less potent in the 1 mM ATP Caliper assay than the pyrrolidine 33a (Table 4). This is likely due to a
higher free energy penalty when binding to the target for this less constrained compound. Gratifyingly, several amine substituents (34b, d, and e) not only showed comparable biochemical potency but also improved microsomal stability, now in an acceptable range of 30% turnover.

Since saturated amines were well tolerated in this position, we next prepared and tested derivatives in which the alkyl groups were linked through a sulfur or oxygen atom (34f and 38). Remarkably, both lost significant activity (at least 10-fold) compared to the corresponding amine derivatives 34b and 34d. It is difficult to reconcile the pronounced loss of activity of compounds 34f and 38 with the wide range of both primary and secondary amines that are tolerated. Computational conformational analysis did not suggest a significant difference in the conformational preference of the oxygen and sulfur-linked substituents compared to the amine substituents. Furthermore, analysis of the available crystal structure did not support the hypothesis that this difference may be driven by different hydrogen-bond pattern, e.g., to water molecules.

Several amino-substituted compounds did however show potent IC₅₀ values suggesting significant scope for further modifications. The neopentyl derivative 34e was particularly promising due to its cellular potency combined with selectivity and improved mouse microsomal stability. As is apparent from the MPS1 IC₅₀ at 1 mM ATP, it was also the most potent derivative in this series.

Table 2. Biochemical, Cellular, And Mouse Microsomal Turnover Data for Compounds Bearing Alternative Aniline Substituents

<table>
<thead>
<tr>
<th>Compd</th>
<th>R</th>
<th>Biochemical IC₅₀ (µM)</th>
<th>Cellular P-MPS1 IC₅₀ (µM)</th>
<th>MLM % (30 min)</th>
<th>AlogP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>MPS1</td>
<td>CDK2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24c</td>
<td></td>
<td>0.008±0.002³</td>
<td>1.28±0.41</td>
<td>73</td>
<td>3.06</td>
</tr>
<tr>
<td>28b</td>
<td></td>
<td>0.024±0.014</td>
<td>0.38 (0.17, 0.59)</td>
<td>63</td>
<td>3.56</td>
</tr>
<tr>
<td>28e</td>
<td></td>
<td>0.010±0.003³</td>
<td>&gt; 45</td>
<td>45</td>
<td>3.41</td>
</tr>
<tr>
<td>28d</td>
<td></td>
<td>0.049 (0.067, 0.030)</td>
<td>&gt; 10</td>
<td>-</td>
<td>45</td>
</tr>
<tr>
<td>28e</td>
<td></td>
<td>0.14±0.05</td>
<td>-</td>
<td>59</td>
<td>2.93</td>
</tr>
</tbody>
</table>

³Results are mean (±SD) for n ≥ 3, or mean values of two independent determinations with individual determinations in parentheses or samples run n = 1. "P-MPS1" indicates an electrochemiluminescence MSD-based cellular assay that measured autophosphorylation of ectopically expressed MPS1 in HCT116 cells. Potency at the lower limit of the dynamic range of the Caliper assay run at 10 µM ATP concentration. IC₅₀ value is likely to be lower than that quoted.

Figure 5. (A) Crystal structure of MPS1 (pale green) bound to 24c (carbon atoms colored orange), extracted from PDB code 5EI8, showing residues (Ile531, Val539, Met671, and Pro673) present in the hydrophobic pocket occupied by 8-position pyrazole. (B) Superimposed crystal structure of MPS1 (pale green) bound to 24c (carbon atoms colored orange), extracted from PDB code 5EI8, onto the structure of MPS1 (not shown) bound to 1 (carbon atoms colored pink), PDB code 4C4J, showing that this is the same pocket occupied by the carbamate group of 1 (carbon atoms colored pink).
We solved the structure of neopentyl 34e bound into MPS1 (Figure 6). Figure 6 shows that the bulkier, more hydrophobic neopentyl substituent of 34e addresses the hydrophobic pocket first mentioned in Figure 5A to a greater extent than the pyrazole substituent of 24c. We hypothesized that an additional increase in potency could be achieved by further increasing the bulk of the hydrophobic substituent.

We thus followed up by synthesizing the two enantiomers 34g and 34h which differ from the neopentyl 34e by an additional methyl group (Table 5). The (S)-enantiomer (34h) particularly, translated into an additional gain in biochemical and cellular potency compared with neopentyl derivative 34e, achieving cellular modulation of MPS1 in the sub-100 nM range (Table 5).

34h showed sufficient selectivity over CDK2 and very good microsomal stability (MLM = 27%). With 34h we had achieved our initial potency goal in the biochemical and cellular assay. Especially considering its moderate molecular weight of 432 Da, 34h represented an extremely potent MPS1 inhibitor with an IC50 = 0.020 μM at 1 mM ATP (corresponding to a Ki of 0.0002 μM)21 and a GI50 value in HCT116 cells of 0.16 μM. Furthermore, the combined SAR suggested significant scope for additional modifications to further optimize the series. This pyrido[3,4-d]pyrimidine (34h) was selective over CDK2 (CDK2/MPS1 Ki ratio > 100),21 Aurora A and B (Table S1), and PLK1 (IC50 > 100 μM) as well as against a wide panel of kinases (Tables S2–S4). Pyrido[3,4-d]pyrimidine 34h inhibited a small number of kinases, namely TNK2, JNK1, JNK2, and LRRK at >80% at 1 μM. JNK1 and JNK2 are considered to be structurally related to MPS1, so follow up IC50 values were obtained (JNK1 IC50 = 0.11 μM, JNK2 IC50 = 0.22 μM), showing that 34h was selective for MPS1 over JNK1 and JNK2 by 100- and 200-fold, respectively.

Next we profiled 34h against a panel of cell lines (Table 6). As expected for an MPS1 inhibitor, 34h showed potent growth inhibition for all cancer cell lines but importantly a significantly higher GI50 for the nontransformed line PNT2.

34h did not inhibit CYP or hERG (Tables S5 and S6). Importantly, pyrido[3,4-d]pyrimidine 34h, showed low turnover in mouse and rat liver microsomes (27 and 24%, after 30 min incubation, respectively), and we progressed the compound to mouse and rat PK experiments, despite a 70% turnover in human liver microsomes, in order to evaluate its suitability for proof of mechanism in vivo experiments. 34h showed moderate clearance (28 and 24 mL/min/kg in mouse and rat, respectively) and high oral bioavailability (68 and 100% in mouse and rat, respectively) with moderate to high volumes of distribution (Table 7).

We thus performed a 3 day pharmacokinetic/pharmacodynamic (PK/PD) study to determine whether biomarker modulation could be achieved in vivo. MPS1 inhibition results in premature exit of cells from mitosis,10e and we therefore chose the mitotic marker phospho-histone H3 as a readout. Histone H3 is specifically phosphorylated at Ser 10 during mitosis.22 Gratifyingly, oral administration of 100 mg/kg of 34h b.i.d. for 3 days to mice bearing HCT116 human colon carcinoma xenografts caused a reduction of the phospho-histone H3 levels compared with vehicle control treated animals at 2 and 6 h, consistent with MPS1 inhibition (Figure 7).

Compound 34h fulfilled all of the criteria we had initially set and compared favorably with our best-in-class 1H-pyrrolo[3,2-c]pyridine (1). Particularly, 34h was devoid of CYP inhibition, did not require an acid labile Boc group for biochemical and
cellular potency, and showed excellent overall selectivity. Its physicochemical properties (AlogP = 4.65 and MW = 432) made 34h a better starting point for further optimization especially given that we had already achieved the targeted potency. Surprisingly, given that it represented a pyrimidine-based kinase scaffold, the 2-amino pyrido[3,4-d]pyrimidine chemotype was relatively unexplored when we initiated this work, with only one published kinase patent application in the public domain.23 Our previously published chemical route16 facilitated the synthesis of a large range of derivatives as well as upscaling of advanced derivatives. We thus nominated 34h as an advanced lead compound.

Table 4. Biochemical, Cellular, And Mouse Microsomal Turnover Data for Compounds Bearing a Saturated Substituent at the 8-Position

<table>
<thead>
<tr>
<th>Compd</th>
<th>R</th>
<th>MPS1 (1 mM ATP)</th>
<th>CDK2</th>
<th>P-MPS1</th>
<th>HCT116 GI50</th>
<th>% (30 min)</th>
<th>AlogP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>IC₅₀</td>
<td>Kᵢ</td>
<td>IC₅₀</td>
<td>Kᵢ</td>
<td></td>
<td></td>
</tr>
<tr>
<td>33a</td>
<td>$\text{N}$</td>
<td>0.010 ± 0.003</td>
<td>0.18 ± 0.001</td>
<td>0.037 ± 0.008</td>
<td>0.15</td>
<td>0.77 ± 0.075</td>
<td>1.71 ± 0.47</td>
</tr>
<tr>
<td>33b</td>
<td>$\text{N}$</td>
<td>0.062 ± 0.010</td>
<td>&gt;1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>34a</td>
<td>$\text{N}$</td>
<td>0.016 ± 0.008</td>
<td>0.37 ± 0.06</td>
<td>0.85 ± 0.43</td>
<td>0.17</td>
<td>1.1 ± 0.07</td>
<td>66 ± 3</td>
</tr>
<tr>
<td>34b</td>
<td>$\text{N}$</td>
<td>0.012 ± 0.005</td>
<td>0.13 ± 0.03</td>
<td>0.19 ± 0.04</td>
<td>0.10</td>
<td>0.22 ± 0.06</td>
<td>0.12 ± 0.04</td>
</tr>
<tr>
<td>34c</td>
<td>$\text{N}$</td>
<td>0.046 ± 0.015</td>
<td>&gt;1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>34d</td>
<td>$\text{N}$</td>
<td>0.011 ± 0.004</td>
<td>0.28 ± 0.08</td>
<td>1.08 ± 0.69</td>
<td>0.43</td>
<td>0.32 ± 0.06</td>
<td>33 ± 3</td>
</tr>
<tr>
<td>34e</td>
<td>$\text{N}$</td>
<td>0.018 ± 0.001</td>
<td>0.045 ± 0.023</td>
<td>0.0005 ± 0.014</td>
<td>0.21</td>
<td>0.14 ± 0.15</td>
<td>0.14 ± 0.14</td>
</tr>
<tr>
<td>34f</td>
<td>$\text{N}$</td>
<td>0.25 ± 0.13</td>
<td>&gt;10</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>38</td>
<td>$\text{N}$</td>
<td>0.15 ± 0.10</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

“Results are mean (±SD) for n ≥ 3, or mean values of two independent determinations with individual determinations in parentheses or samples run n = 1. "P-MPS1" indicates an electrochemiluminescence MSD-based cellular assay that measured autophosphorylation of ectopically expressed MPS1 in HCT116 cells. "HCT116 GI₅₀" indicates a cell proliferation assay carried out by colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in HCT116 cells. Potency at the lower limit of the dynamic range of the Caliper assay run at 10 μM ATP concentration. IC₅₀ value is likely to be lower than that quoted.
CONCLUSIONS

By merging two distinct chemical series, namely 1H-pyrrolo[3,2-c]pyridines and 1H-pyrazolo[4,3-c]pyridines, we successfully fulfilled our aim to discover a new class of MPS1 inhibitors that did not require an acid labile Boc group for potent inhibition. The pyrido[3,4-d]pyrimidine core was unprecedented for kinases, and our structure guided optimization resulted in potent MPS1 inhibitors of substantially reduced size and lipophilicity compared with the parent 1H-pyrrolo[3,2-c]-pyridines. Moreover, our optimized compound 34h was devoid of CYP inhibition and proved to be extremely potent in the MPS1 biochemical assay with the ability to target this kinase in cells and to induce significant growth inhibition at nanomolar concentrations. A screen against a large sample of the human kinome revealed a high level of selectivity, especially with regard to mitotic kinases. Most importantly, pyrido[3,4-d]pyrimidine 34h showed a satisfactory pharmacokinetic profile in rodents and effectively inhibited MPS1 activity in vivo.

Optimization of the remaining issues associated with 34h, in particular HLM instability and plasma protein binding, as well as the investigation of advanced compounds in combination efficacy models, is ongoing and the results will be reported in due course.

Table 5. Biochemical, Cellular, And Mouse Microsomal Turnover Data for Enantiomers 34g and 34h

<table>
<thead>
<tr>
<th>Compd</th>
<th>R</th>
<th>Biochemical activity (μM)</th>
<th>Cellular activity (μM)</th>
<th>MLM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>MPS1 (1 mM ATP)</td>
<td>CDK2</td>
<td>P-MPS1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IC₅₀</td>
<td>Kᵢ</td>
<td>IC₅₀</td>
</tr>
<tr>
<td>34g</td>
<td></td>
<td>0.018 ± 0.001³</td>
<td>0.045 ± 0.023</td>
<td>0.45 ± 0.21</td>
</tr>
<tr>
<td>34g</td>
<td></td>
<td>0.022 ± 0.014³</td>
<td>0.42 ± 0.23</td>
<td>0.47 ± 0.25</td>
</tr>
<tr>
<td>34h</td>
<td></td>
<td>0.011 ± 0.000³</td>
<td>0.020 ± 0.002</td>
<td>0.56 ± 0.28</td>
</tr>
</tbody>
</table>

Table 6. GI₅₀ Values for 34h in 3 Day MTT Assay Carried out on Panel of Cell Lines

<table>
<thead>
<tr>
<th>origin</th>
<th>cell line</th>
<th>GI₅₀ (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>colon</td>
<td>SW620</td>
<td>0.065</td>
</tr>
<tr>
<td>head and neck</td>
<td>CAL27</td>
<td>0.23</td>
</tr>
<tr>
<td>breast</td>
<td>CAL51</td>
<td>0.068</td>
</tr>
<tr>
<td>pancreatic</td>
<td>Miapaca-2</td>
<td>0.25</td>
</tr>
<tr>
<td>ovarian</td>
<td>RMG1</td>
<td>0.110</td>
</tr>
<tr>
<td>prostate</td>
<td>PNT2</td>
<td>3.95</td>
</tr>
</tbody>
</table>

*“GI₅₀” indicates a cell proliferation assay carried out by colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in a panel of cell lines.

**Results are mean (±SD) for n ≥ 3, or mean values of two independent determinations with individual determinations in parentheses or samples run n = 1. “P-MPS1” indicates an electrochemiluminescence MSD-based cellular assay that measured autophosphorylation of ectopically expressed MPS1 in HCT116 cells. “HCT116 GI₅₀” indicates a cell proliferation assay carried out by colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in HCT116 cells. Potency at the lower limit of the dynamic range of the Caliper assay run at 10 μM ATP concentration. IC₅₀ value is likely to be lower than that quoted.
Table 7. Mouse and Rat Blood Pharmacokinetics of 34h at 5 mg/kg iv and po

<table>
<thead>
<tr>
<th>species</th>
<th>t1/2 (h)</th>
<th>CI (mL/min/kg)</th>
<th>Cmax(\text{ppb}) (nmol/L)</th>
<th>AUC(\text{ppb}) (nmol-h/L)</th>
<th>PBB (%)</th>
<th>Vz (L/kg)</th>
<th>F (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>mouse</td>
<td>8.2</td>
<td>28</td>
<td>770</td>
<td>4800</td>
<td>99.98</td>
<td>14.7</td>
<td>68</td>
</tr>
<tr>
<td>rat</td>
<td>2.5</td>
<td>24</td>
<td>560</td>
<td>9300</td>
<td>99.97</td>
<td>4.64</td>
<td>100</td>
</tr>
</tbody>
</table>

*Only detected to 4 h.

Figure 7. (A,B) Representative immunoblots of phospho-histone H3 showing dose-dependent PD modulation in HCT116 human tumor xenografts, following 100 mg/kg b.i.d. dosing of 34h for 3 consecutive days. Total histone H3, cleaved poly ADP ribose polymerase (PARP, a measure of apoptosis) and glyceraldehyde 3-phosphate dehydrogenase (GADPH, for protein loading) are also shown. (C) Phospho-histone H3 versus total histone H3 ratio for control and treated samples at 2 and 6 h after last dose. Asterisks show statistically significant differences from control groups as determined by one-way ANOVA.

**EXPERIMENTAL SECTION**

General Chemistry Information. Starting materials, reagents, and solvents for reactions were reagent grade and used as purchased. Chromatography solvents were HPLC grade and were used without further purification. Thin-layer chromatography analysis was performed using silica gel 60 F-254 thin-layer plates. Flash column chromatography and glyceraldehyde 3-phosphate dehydrogenase (GADPH, for protein loading) are also shown. (C) Phospho-histone H3 versus total histone H3 ratio for control and treated samples at 2 and 6 h after last dose. Asterisks show statistically significant differences from control groups as determined by one-way ANOVA.

![Image](https://example.com/image.png)
Preparation of Compounds 24a, 24d, 28a, and 28b).

A solution of 8-chloro-2-(methylthio)pyrido[3,4-d]pyrimidine 16 (480 mg, 2.27 mmol), (1-methyl-1H-pyrazol-4-yl)boronic acid (11 mg, 0.13 mmol), PCy3 (3 mg, 0.013 mmol), sodium bicarbonate (0.60 mmol), and 8-cyclopropyl-2-(methylthio)pyrido[3,4-d]pyrimidine 16 (25 mg, 0.068 mmol) in 1,4-dioxane/water (3:1, 0.60 mL) was heated to 80 °C under microwave irradiation for 1.5 h and then to 100 °C for 1.5 h. The mixture was concentrated onto silica gel and purified by flash column chromatography (0–100% EtOAc in cyclohexane) to give the title compound (20 mg, 43%). HRMS (ESI) m/z calc for C12H12N5O2S (M + H) 290.0706, found 290.0722.

N-(4-Methoxyphenyl)-2-(1-methyl-1H-pyrazol-4-yl)pyrido[3,4-d]pyrimidin-2-amine 24a. To a solution of 8-(1-methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrido[3,4-d]pyrimidine 19 (29 mg, 0.10 mmol) in DMSO (4 mL) was added cesium carbonate (59 mg, 0.18 mmol) and N-(4-methoxyphenyl)formamide (15 mg, 0.10 mmol). The mixture was heated to 100 °C for 18 h. The mixture was diluted with EtOAc and water. The aqueous layer was re-extracted with EtOAc. The combined organic layers were washed with water, dried, and concentrated in vacuo. The residue was purified by flash column chromatography (0–10% MeOH in CH2Cl2), followed by SCX-2 cartridge (MeOH - 1 M NH4 in MeOH) to give the title compound (3 mg, 24%). HRMS (ESI) m/z calc for C16H16N6O (M + H) 333.1771, found 333.1773. 1H NMR (500 MHz, CD3OD) δ 4.90 (s, 1H), 8.54 (s, 1H), 8.41 (d, J = 8.3 Hz, 1H), 8.28 (d, J = 5.3 Hz, 1H), 8.17 (d, J = 0.9 Hz, 1H), 7.90 (d, J = 0.8 Hz, 1H), 7.56 (d, J = 5.3 Hz, 1H), 7.30 (d, J = 1.8 Hz, 1H), 7.25 (d, J = 8.2, 1.8 Hz, 1H), 3.96 (s, 3H), 3.88 (s, 3H), 3.24 (m, 1H), 1.16–1.08 (m, 4H).

Preparation of Formamidines 26b–e (Exemplified by Preparation of Compound 26b).

To a solution of 8-(1-methyl-1H-pyrazol-4-yl)-2-(methylthio)pyrido[3,4-d]pyrimidin-2-amine 26 (20 mg, 0.094 mmol) in THF (15 mL) and sodium carbonate (2.27 mmol) in 2,2,2-trichloroethanol (0.7 mL) was heated to 130 °C under microwave irradiation for 1.5 h. The reaction was diluted with EtOAc and quenched with aqueous sat. sodium bicarbonate. The aqueous layer was extracted with EtOAc, and the combined organic layers were washed with water and brine, dried, and concentrated in vacuo. The residue was purified by flash column chromatography (0–10% MeOH in EtOAc) to give the title compound (20 mg, 43%). HRMS (ESI) m/z calc for C16H16N6O (M + H) 333.1771, found 333.1773. 1H NMR (500 MHz, CD3OD) δ 4.90 (s, 1H), 8.54 (s, 1H), 8.41 (d, J = 8.3 Hz, 1H), 8.28 (d, J = 5.3 Hz, 1H), 8.17 (d, J = 0.9 Hz, 1H), 7.90 (d, J = 0.8 Hz, 1H), 7.56 (d, J = 5.3 Hz, 1H), 7.30 (d, J = 1.8 Hz, 1H), 7.25 (d, J = 8.2, 1.8 Hz, 1H), 3.96 (s, 3H), 3.88 (s, 3H), 3.24 (m, 1H), 1.16–1.08 (m, 4H).

N-(4-Methoxyphenyl)-2-(1-methyl-1H-pyrazol-4-yl)phenylpyrido[3,4-d]pyrimidin-2-amine 24b. To a solution of 8-(1-methyl-1H-pyrazol-4-yl)-2-(methylamine)phenylpyrido[3,4-d]pyrimidin-2-amine 26b (40 mg, 0.19 mmol) in THF (4 mL) was added sodium hydride (60% w/w dispersion in oil, 0.30 mmol). The reaction mixture was stirred at rt for 10 min. The mixture was cooled to 0 °C and 8-chloro-2-(methylthio)pyrido[3,4-d]pyrimidine 25 (60 mg, 0.24 mmol) was added. The mixture was stirred for 18 h while slowly warming to rt and then concentrated in vacuo. The residue was partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc. The combined organic layers were washed with water and brine, dried, and concentrated in vacuo. The residue was purified by flash column chromatography (0–5% MeOH in EtOAc) to give the title compound (79 mg, 25%). HRMS (ESI) m/z calc for C16H16N6O (M + H) 333.1771, found 333.1773. 1H NMR (500 MHz, CD3OD) δ 7.93 (s, 1H), 7.80 (s, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.44 (d, J = 2.0 Hz, 1H), 7.38 (d, J = 8.0, 2.0 Hz, 1H), 3.92 (s, 3H), 2.31 (s, 3H).

N-(4-Methoxyphenyl)-2-(1-methyl-1H-pyrazol-4-yl)phenylpyrido[3,4-d]pyrimidin-2-amine 26b. To a solution of 8-(1-methyl-1H-pyrazol-4-yl)-2-(methylthio)pyrido[3,4-d]pyrimidine 18 (127 mg, 0.584 mmol) in CH2Cl2 (5 mL) was treated with MCPBA (77% w/w, 290 mg, 1.29 mmol) at 0 °C and then allowed to react at rt for 18 h. The mixture was quenched with water and extracted with CH2Cl2. The combined organic layers were washed with water, dried, and concentrated in vacuo. The residue was purified by flash column chromatography (0–100% EtOAc in cyclohexane) to give the title compound (18 mg, 28%). HRMS (ESI) m/z calc for C16H15N3O2S (M + H) 351.1119, found 351.1111. 1H NMR (500 MHz, CDCl3) δ 9.17 (s, 1H), 8.26 (d, J = 5.0 Hz, 1H), 7.79 (s, 1H), 7.63 (s, 1H), 7.52 (d, J = 5.0 Hz, 1H), 7.47 (d, J = 8.0, 2.0 Hz, 1H), 7.42 (m, 1H), 7.39 (d, J = 2.0 Hz, 1H), 3.98 (s, 3H), 2.44 (s, 3H).

N-(4-Methoxyphenyl)-2-(1-methyl-1H-pyrazol-4-yl)phenylpyrido[3,4-d]pyrimidin-2-amine 26c. To a solution of 8-(1-methyl-1H-pyrazol-4-yl)-2-(methylthio)pyrido[3,4-d]pyrimidine 18 (127 mg, 0.584 mmol) in CH2Cl2 (5 mL) was treated with MCPBA (77% w/w, 290 mg, 1.29 mmol) at 0 °C and then allowed to react at rt for 18 h. The mixture was quenched with water and extracted with CH2Cl2. The combined organic layers were washed with water, dried, and concentrated on silica. The residue was purified by flash column chromatography (0–70% EtOAc in cyclohexane) to give the title compound (128 mg, 68%). HRMS (ESI) m/z calc for C16H16N3O2S (M + H) 351.1119, found 351.1111. 1H NMR (500 MHz, CDCl3) δ 9.17 (s, 1H), 8.26 (d, J = 5.0 Hz, 1H), 7.79 (s, 1H), 7.63 (s, 1H), 7.52 (d, J = 5.0 Hz, 1H), 7.47 (d, J = 8.0, 2.0 Hz, 1H), 7.42 (m, 1H), 7.39 (d, J = 2.0 Hz, 1H), 3.98 (s, 3H), 2.44 (s, 3H).
mmol). The reaction was heated to 100 °C under microwave irradiation for 30 min. The reaction was diluted with EtOAc and water, dried, and concentrated in vacuo. The residue was purified by flash column chromatography (0–100% EtOAc in cyclohexane) followed by SCX-2 cartrige (MeOH - 1 M NH₄OH in MeOH) to give the title compound (8 mg, 29%). HRMS (ESI) m/z calcd for C₂₆₇H₂₄N₇O (M + H) 402.2037, found 402.2034. 1H NMR (500 MHz, CDCl₃) δ 7.37 (s, 1H), 8.06 (d, J = 8.5 Hz, 1H), 8.05 (d, J = 5.5 Hz, 1H), 8.11–8.09 (m, 2H), 7.97 (s, 1H), 7.82 (s, 1H), 7.79 (d, J = 5.5 Hz, 1H), 7.61–7.59 (m, 3H), 7.19 (d, J = 2.0 Hz, 1H), 6.99 (dd, J = 8.5, 2.0 Hz, 1H), 4.02 (s, 3H), 3.95 (s, 3H).

1-(Methyl-1H-pyrazol-4-yl)-(N-2-(methyl-1H-pyrazol-4-yl)phenyl)pyrido[3,4-d]pyrimidin-2-amine 34b. To a solution of 8-chloro-N-(2-phenyl)pyrido[3,4-d]pyrimidin-2-amine 28b (12 mg, 0.034 mmol) in 1,4-dioxane/water (2:1, 3 mL) were added 1-iodo-4-(4,5,5-trimethyl-1,3,2-dioxaborolano-2-yl)-1H-pyrazole (14 mg, 0.068 mmol), cesium carbonate (17 mg, 0.051 mmol) and Pd(PPh₃)₄ (2 mg, 1.7 μmol). The reaction mixture was heated to 100 °C under microwave conditions for 30 min. The reaction mixture was diluted with EtOAc and water. The combined organics were washed with water and brine, dried, and concentrated in vacuo. The residue was purified by flash column chromatography (0–15% MeOH in EtOAc) to give the title compound (62 mg, 45% over two steps). LCMS (ESI) found 409.1771. 1H NMR (500 MHz, (CD₃)₂SO) δ 8.14 (s, 1H), 7.88 (d, J = 5.5 Hz, 1H), 7.84 (s, 1H), 7.19 (d, J = 2.0 Hz, 1H), 7.17 (d, J = 8.5 Hz, 1H), 6.99 (dd, J = 8.5, 2.0 Hz, 1H), 4.02 (s, 3H), 3.95 (s, 3H).

Preparation of Compounds in Scheme 3 (Exemplified by the Preparation of 33a). 2-(Methylsulfonyl)-8-(pyridin-1-yl)pyrido[3,4-dipyrimeidine 31a. A mixture of 8-chloro-2-(methylythio)pyrido[3,4-d]pyrimidine 16 (105 mg, 0.496 mmol) and pyridine (425 μL, 5.10 mmol) in NMP (2.5 mL) was stirred at 135 °C for 40 min. The reaction mixture was heated to 130 °C to give the title compound (19 mg, 52%). HRMS (ESI) m/z calcd for C₂₃H₂₃N₇O (M + H) 402.2047, found 402.2043. 1H NMR (500 MHz, CDCl₃) δ 9.37 (s, 1H), 8.56 (d, J = 8.5 Hz, 1H), 8.50 (d, J = 5.5 Hz, 1H), 8.11–8.09 (m, 2H), 7.97 (s, 1H), 7.82 (s, 1H), 7.79 (d, J = 5.5 Hz, 1H), 7.61–7.59 (m, 3H), 7.19 (d, J = 2.0 Hz, 1H), 6.99 (dd, J = 8.5, 2.0 Hz, 1H), 4.02 (s, 3H), 3.95 (s, 3H).
hydroxide (2 M, 1 mL) and MeOH (1 mL) were added, and the resulting mixture stirred at rt for 3 h. The mixture was concentrated in vacuo. The residue was partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc, and the combined organics were washced with water and brine, dried, and concentrated in vacuo. The residue was purified by flash column chromatography (0–75% EtOAc in cyclohexane) to give the title compound (27 mg, 52%). HRMS (ESI) m/z calc for C22H23N6O2 (M + H) 403.1877, found 403.1871. 1H NMR (500 MHz, (CD3)2SO) δ 9.31 (s, 1H), 8.61 (s, 1H), 8.39 (s, 1H), 8.17 (d, J = 0.8 Hz, 1H), 7.94–7.84 (m, 2H), 7.35 (d, J = 5.6 Hz, 1H), 7.28 (d, J = 1.8 Hz, 1H), 7.19 (d, J = 3.5, 1H), 4.33 (d, J = 6.9 Hz, 2H), 3.94 (s, 3H), 3.88 (s, 3H), 1.40 (m, 1H), 0.68–0.59 (m, 2H), 0.49–0.39 (m, 2H).

Biochemical Assays. MPS1, CDK2, and Aurora A and B co-screen assays were performed as reported previously.

MPS Assay. IC50 of MPS1 autophosphorylation inhibition at pT333/y337 sites in HCT116 cells was determined by an electroluminescence assay (Meso Scale Discovery, MSD) as described previously.

Cell Viability Assay. Cell proliferation assays were carried out by colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro- mide (MTT) assay (Sigma) in HCT116 cells as described previously.

Crystallization. The kinase domain (residues S19–808) of MPS1 was produced in E. coli and purified as described previously. For compound 39, apo crystals of MPS1 were grown in PEG300 as previously described prior to soaking in a fresh solution containing 35% PEG300, 1 mM inhibitor, and 1% (v/v) DMSO for 24 h. The crystals were cryo-protected in soak solution supplemented with 22.5% ethylene glycol prior to flash cooling in liquid nitrogen.

Co-crystals of MPS1 with compound S11 were grown at 18 °C using the sitting-drop vapor-diffusion method. The crystallographic drops were composed of 2 μL of protein/ligand solution (8.9 mg/mL protein and 5 mM S11) and 2 μL of reservoir solution placed over 200 μL of reservoir solution of 18–26% (w/v) PEG3350, 0.1 M bis-Tris propane pH 7.5, 0.1 M MgCl2, and 0.1 mM sodium formate in 48-well plates. Co-crystals typically grew in 12–16 h. Crystals of MPS1 with S11 were transferred to backsoaking solutions containing reservoir solution also containing 200 mM of inhibitor and up to 20% (v/v) DMSO and incubated at 18 °C for 24–48 h. Crystals were cryo-protected with para-nitro-Oil prior to flash cooling in liquid nitrogen.

Co-crystals of MPS1 with compound 34e were grown at 18 °C using the sitting-drop vapor-diffusion method. The crystallographic drops were composed of 2 μL of protein/ligand solution (11.4 mg/mL protein and 2 mM 34e) with 20% (w/v) PEG3350, 0.1 M bis-Tris propane pH 7.5, and 0.2 M sodium formate. Crystals were cryo-protected with para- nOil prior to flash cooling in liquid nitrogen.

Data Collection, Structure Solution, and Refinement. X-ray diffraction data were collected at 100 K at Diamond Light Source (Oxfordshire, U.K.) or in-house on a Rigaku FRX with Pilatus 300 K detector. Data were integrated with XDS25 or MOSFLM (S11 data set only). All data were imported to MTZ format with POINTLESS.28 Then scaled and merged with AIMLESS. All data were imported to MTZ format with POINTLESS,26 and refinement with BUSTER.29 TLS groups were selected with PHENIX phenix.30 Ligand restraints were generated with GRADE31 and MOGUL.35 The final structure quality was checked with MOLPROBITY.33 The data collection and refinement statistics are presented in Table S7.

Microsomal Metabolism. Microsomal turnover was carried out in male CD1 mice, female Sprague–Dawley rats, and pooled human liver microsomes obtained from Tebu-Bio (Petersborough, U.K.) following 30 min incubation of 10 μM compound in 1 mg/mL microsomal protein, 3 mmol/L MgCl2, 1 mmol/L NADPH, 2.5 mmol/L UDP-glucuronic acid, and 10 mmol/L phosphate buffer (pH 7.4) (all purchased from Sigma-Aldrich, Gillingham, U.K.). Reactions, at 37 °C, were started by addition of the test compound and were terminated at 0 and 30 min by the addition of 3 volumes of ice-cold methanol containing internal standard. Samples were centrifuged at 2800g for 30 min at 4 °C and the supernatants analyzed. Control incubations were prepared as above with omission of cofactors. Compound measurements were performed by LCMS on an Agilent quadrupole time-of-flight instrument (Agilent 6510) following separation with a 6 min gradient of 10 mM ammonium acetate in methanol on a 50 × 2.1 mm 2.6μm particles C18 column (Kinetex Phenomenex). For metabolite identification, the gradient was extended to 20 min, and MS/MS carried out with fragment elucidation for ions of interest.

Pharmacokinetic Studies. All in vivo studies were performed in accordance with U.K. Home Office regulations, ICR ethical review processes, and U.K. National Cancer Research Institute guidelines.54 Female Balb/C mice and Sprague–Dawley rats were obtained from Charles River (Margate, U.K.). Animals were adapted to laboratory conditions for at least 1 week prior to dosing and were allowed food and water ad libitum. Compounds were administered iv or po (mouse: 0.1 mL/10g in 10% DMSO, 5% tween 20 in saline, rat: 0.05 mL/10g in 10% DMSO, 5% tween 20 in saline). Blood samples were collected from the tail vein (20 μL) at 8 time points over the 24 h post dose and spotted on Whatman B cards together with a standard curve and quality controls spiked in control blood. Cards were allowed to dry at rt for at least 6 h. Cards were punched, and 6 mm discs were extracted with 200 μL methanol containing 500 nM olomoucine as an internal standard. Following centrifugation, extracts were analyzed by multiple reaction monitoring of precursor and product ions by ESI-LCMS/MS on a QTRAP 4000 (ABSciex) following separation as above. Quantitation was carried out with an external calibration (8 points ranging from 1 nM to 25 μM). Quality controls were included (3 concentrations) at the beginning and the end of the analytical run and were within 20% of nominal concentrations.

Pharmacokinetic parameters were derived from noncompartmental analysis WinNonLin (model 200 and 201) Pharsight version.

In Vivo Proof-of-Concept Studies. Animals (6–8 week old female NCr athymic mice) were supplied by a commercial breeder and fed sterilized food and water ad libitum.

PK/PD Study. Three million HCT116 human colorectal carcinoma cells were injected s.c. bilaterally into the flanks. Dosing commenced when tumors reached a mean diameter of 8–10 mm (day 14). Animals (n = 6 per group) were dosed twice daily with compound 34h (100 mg/ kg po) or vehicle (10% DMSO, 5% Tween 20, 85% saline) over 3 days (6 doses), and groups of three were culled at 2 or 6 h after the final dose. Heparized plasma and tumor samples were collected and snap frozen for pharmacokinetic (PK) and pharmacodynamic (PD) biomarker analysis.

PD Assays. For PD analysis, frozen tumor samples were homogenized in RIPA lysis buffer (150 mM NaCl, 50 mM Tris pH 7.5, 1 mM EDTA pH 8.0, 1% NP40, 1% sodium deoxycholate, 1% sodium dodecyl sulfate, and supplemented with protease and phosphatase inhibitors), sonicated, and centrifuged to clear the debris. Protein concentrations of the supernatants were measured, and μg protein for each sample was loaded onto LDS-PAGE (Life Technologies). Proteins were separated, transferred to nitrocellulose membrane, and probed with phospho-histone H3 (Millipore), total-histone H3 (Abcam), cleaved-PARP (Cell Signaling), and GAPDH (Millipore) antibodies. Blots were quantified using ImageJ and analyzed with Graphpad Prism.
Crystallographic analysis of compounds 15b, 24b, 24c, 34e, 39 bound to MPS1 (PDF)

Accession Codes

Atomic coordinates and structure factors for compounds 1, 15b, 24b, 24c, 34e and 39 can be accessed using PDB codes 4CJH, 5E16, 5E12, 5E18, 5EH0, 5EHY, respectively.

AUTHOR INFORMATION

Corresponding Author

*E-mail: swen.hoelder@icr.ac.uk. Phone: +44 (0)2087224353.

Present Address

SBA School of Science and Engineering, Lahore University of Management Sciences, D.H.A, Lahore 54792, Pakistan.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported by Cancer Research U.K. [grant number C309/A11566]. We also acknowledge the Cancer Research Technology Pioneer Fund and Sixth Element Capital for funding (to P.I.) and NHS funding to the NIHR Biomedical Research Centre. S.L. is also supported by Breakthrough Breast Cancer Discovery; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PARP, poly ADP ribose polymerase; MPS1, monopolar spindle kinase 1; MSD, Meso Scale Discovery; PLK1, polo-like kinase 1; PTEN, phosphatase and tensin homologue; SAC, spindle assembly checkpoint; RLM, rat liver microsomes; TTK, a novel human protein kinase, is associated with cell cycle abnormalities in human cancer.

REFERENCES


